UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934 For the quarterly period ended August 31, 2008
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934 For the transition period from _______________ to ______________
Commission File Number: 0-18105
VASOMEDICAL, INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 11-2871434
--------------------------------------------------------------------------------
(State or other jurisdiction of (IRS Employer Identification Number)
incorporation or organization)
180 Linden Ave., Westbury, New York 11590
--------------------------------------------------------------------------------
(Address of principal executive offices)
Registrant's Telephone Number (516) 997-4600
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
--- --
Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, or a non-accelerated filer.
Large Accelerated Filer [ ] Accelerated Filer [ ] Non-Accelerated Filer [ X ]
Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act).
Yes [ ] No [X]
--- --
Number of Shares Outstanding of Common Stock, $.001 Par Value, at October
15, 2008 93,868,004
Vasomedical, Inc. and Subsidiaries
INDEX
Page
----
PART I - FINANCIAL INFORMATION
Item 1 - Financial Statements (unaudited)
Consolidated Condensed Balance Sheets as of
August 31, 2008 and May 31, 2008 3
Consolidated Condensed Statements of Operations for the
Three Months Ended August 31, 2008 and 2007 4
Consolidated Condensed Statement of Changes in Stockholders'
Equity for the Period from June 1, 2008 to August 31, 2008 5
Consolidated Condensed Statements of Cash Flows for the
Three Months Ended August 31, 2008 and 2007 6
Notes to Consolidated Condensed Financial Statements 7
Item 2 - Management's Discussion and Analysis of Financial Condition
and Results of Operations 14
Item 3 - Controls and Procedures 33
PART II - OTHER INFORMATION
Item 1 - Legal Proceedings 34
Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 34
Item 3 - Defaults upon Senior Securities 34
Item 4 - Submission of Matters to a Vote of Security Holders 34
Item 5 - Other Information 34
Item 6 - Exhibits 34
Page 2
ITEM 1. FINANCIAL STATEMENTS
Vasomedical, Inc. and Subsidiaries
CONSOLIDATED CONDENSED BALANCE SHEETS
August 31, 2008 May 31, 2008
------------------ ------------------
ASSETS (Unaudited) (Derived from
audited financial
statements)
CURRENT ASSETS
Cash and cash equivalents $ 2,140,403 $ 2,653,999
Accounts receivable, net of an allowance for doubtful accounts of
$135,617 at August 31, 2008, and $270,183 at May 31, 2008 881,685 717,849
Inventories, net 1,826,445 1,652,678
Other current assets 135,310 58,933
------------------ ------------------
Total current assets 4,983,843 5,083,459
PROPERTY AND EQUIPMENT, net of accumulated depreciation of
$2,057,558 at August 31, 2008, and $2,178,566 at May 31, 2008 60,052 57,170
DEFERRED DISTRIBUTOR COSTS, net of accumulated amortization of
$127,219 at August 31, 2008, and $101,775 at May 31, 2008 381,657 407,101
OTHER ASSETS 201,610 213,336
------------------ ------------------
$ 5,627,162 $ 5,761,066
================== ==================
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable and accrued expenses $ 1,151,831 $ 822,244
Sales tax payable 138,023 149,304
Deferred revenue 1,151,556 1,132,445
Deferred gain on sale of building 53,245 53,245
Accrued professional fees 52,563 74,320
------------------ ------------------
Total current liabilities 2,547,218 2,231,558
LONG-TERM LIABILITIES
Deferred revenue 511,126 485,608
Accrued rent expense 11,542 8,656
Deferred gain on sale of building 155,299 168,610
Other long-term liabilities 80,000 -
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value; 1,000,000 shares authorized;
none issued and outstanding - -
Common stock, $.001 par value; 110,000,000 shares authorized;
93,768,004 shares at August 31, 2008, and 93,768,004 at
May 31, 2008, issued and outstanding 93,768 93,768
Additional paid-in capital 48,073,746 48,068,432
Accumulated deficit (45,845,537) (45,295,566)
------------------ ------------------
Total stockholders' equity 2,321,977 2,866,634
------------------ ------------------
$ 5,627,162 $ 5,761,066
================== ==================
The accompanying notes are an integral part of these consolidated condensed financial
statements
Page 3
Vasomedical, Inc. and Subsidiaries
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
Three months ended August 31,
--------------------------------------
2008 2007
----------------- -----------------
Revenues
Equipment sales $ 656,496 $ 493,268
Equipment rentals and services 655,225 846,808
----------------- -----------------
Total revenues 1,311,721 1,340,076
Cost of Sales and Services
Cost of sales, equipment 528,281 340,638
Cost of equipment rentals and services 282,878 314,699
----------------- -----------------
Total cost of sales and services 811,159 655,337
----------------- -----------------
Gross profit 500,562 684,739
----------------- -----------------
Operating Expenses
Selling, general and administrative 943,759 558,156
Research and development 132,347 139,175
----------------- -----------------
Total operating expenses 1,076,106 697,331
----------------- -----------------
Loss from operations (575,544) (12,592)
----------------- -----------------
Other Income (Expenses)
Interest and financing costs - (16,666)
Interest and other income, net 16,012 12,331
Recognition of deferred gain on sale of building 13,311 4,437
----------------- -----------------
Total other income (expenses) 29,323 102
----------------- -----------------
Loss before income taxes (546,221) (12,490)
Income tax expense, net (3,750) (6,296)
----------------- -----------------
Net loss $ (549,971) $ (18,786)
================= =================
Net loss per common share
- basic $ (0.01) $ (0.00)
================= =================
- diluted $ (0.01) $ (0.00)
================= =================
Weighted average common shares outstanding
- basic 93,768,004 87,748,778
================= =================
- diluted 93,768,004 87,748,778
================= =================
The accompanying notes are an integral part of these consolidated condensed financial
statements
Page 4
Vasomedical, Inc. and Subsidiaries
CONSOLIDATED CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
(Unaudited)
Additional Total
Common Stock Paid-in Accumulated Stockholders'
Shares Amount Capital Deficit Equity
----------------- ----------------- ----------------- ----------------- --------------
Balance at June 1, 2008 93,768,004 $ 93,768 $ 48,068,432 $ (45,295,566) $ 2,866,634
Stock-based compensation 5,314 5,314
Net loss (549,971) (549,971)
----------------- ----------------- ----------------- ----------------- --------------
Balance at August 31, 2008 93,768,004 $ 93,768 $ 48,073,746 $ (45,845,537) $ 2,321,977
================= ================= ================= ================= ==============
The accompanying notes are an integral part of these consolidated condensed financial
statements
Page 5
Vasomedical, Inc. and Subsidiaries
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended August 31,
-------------------------------------
2008 2007
----------------- -----------------
Cash flows provided by (used in) operating activities
Net loss $ (549,971) $ (18,786)
Adjustments to reconcile net loss to net cash provided by
(used in) operating activities
Depreciation and amortization 29,497 70,060
Amortization of deferred gain on sale of building (13,311) (4,437)
Provision for doubtful accounts - (25,456)
Amortization of deferred distributor costs 25,444 25,444
Expenses paid for distributor agreement - (40,490)
Stock based compensation 5,314 61,786
Changes in operating assets and liabilities:
Accounts receivable (163,836) 316,234
Inventories (193,041) 216,928
Other current assets (76,377) (202,549)
Accounts payable, accrued expenses and other current liabilities 318,546 (198,823)
Other liabilities 105,518 (94,915)
----------------- -----------------
37,754 123,782
----------------- -----------------
Net cash provided by operating activities (512,217) 104,996
----------------- -----------------
Cash flows provided by (used in) investing activities
Proceeds from the building sale - 1,400,000
Expenses paid for sale of building - (89,143)
Purchases of fixed assets (1,379) -
----------------- -----------------
Net cash provided by (used in) investing activities (1,379) 1,310,857
----------------- -----------------
Cash flows provided by (used in) financing activities
Payments on long term debt and notes payable - (851,015)
Proceeds from Securities Purchase agreement - 1,500,000
Expenses paid in relation to Securities Purchase Agreement - (124,110)
----------------- -----------------
Net cash provided by financing activities - 524,875
----------------- -----------------
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (513,596) 1,940,728
----------------- -----------------
Cash and cash equivalents - beginning of period 2,653,999 850,288
----------------- -----------------
Cash and cash equivalents - end of period $ 2,140,403 $ 2,791,016
================= =================
Non-cash investing and financing activities were as follows:
Inventories transferred to property and equipment, attributable
to operating leases, net $ 19,274 $ (38,531)
Common stock issued for distribution agreement $ - $ 468,386
Supplemental Disclosures
Interest paid $ - $ 16,666
Income taxes paid $ 665 $ 2,983
The accompanying notes are an integral part of these consolidated condensed financial
statements
Page 6
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited)
August 31, 2008
NOTE A - ORGANIZATION AND PLAN OF OPERATIONS
Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the
context requires otherwise, all references to "we", "our", "us", "Company",
"registrant", "Vasomedical" or "management" refer to Vasomedical Inc. and its
subsidiaries. Since 1995, we have been primarily engaged in designing,
manufacturing, marketing and supporting EECP(R) enhanced external
counterpulsation systems based on our unique proprietary technology currently
indicated for use in cases of stable or unstable angina (i.e., chest pain),
congestive heart failure (CHF), acute myocardial infarction (i.e., heart attack,
(MI)) and cardiogenic shock. The EECP(R) therapy system is a non-invasive,
outpatient therapy for the treatment of diseases of the cardiovascular system.
The therapy serves to increase circulation in areas of the heart with less than
adequate blood supply and helps to restore systemic vascular function. The
therapy also increases blood flow and oxygen supply to the heart muscle and
other organs and decreases the heart's workload and need for oxygen, while also
improving function of the endothelium, the lining of blood vessels throughout
the body, lessening resistance to blood flow. We provide hospitals, clinics and
physician private practices with EECP(R) equipment, treatment guidance, and a
staff training and equipment maintenance program designed to provide optimal
patient outcomes. EECP(R) is a registered trademark for our enhanced external
counterpulsation therapy and systems. For more information, visit
www.vasomedical.com.
We have Food and Drug Administration (FDA) clearance to market our EECP(R)
therapy for use in the treatment of stable and unstable angina, congestive heart
failure, acute myocardial infarction, and cardiogenic shock, however, our
current marketing efforts are limited to the treatment of chronic stable angina
and congestive heart failure. Medicare and other third-party payers currently
reimburse for the treatment of angina pectoris patients with moderate to severe
symptoms who are refractory to medications and not candidates for invasive
procedures, including patients with serious co-morbidities, such as heart
failure, diabetes, and peripheral vascular disease. Patients with primary
diagnoses of heart failure, diabetes, and peripheral vascular disease are also
reimbursed under the same criteria, provided the primary indication for
treatment with EECP(R) therapy is angina symptoms.
During the last several years we incurred operating losses. We have
attempted to achieve profitability by reducing operating costs and halting the
trend of declining revenue, and to reduce cash usage through bringing our cost
structure more into alignment with current revenues. By engaging in
restructurings during March 2007 and April 2007, the Company has substantially
reduced personnel and spending on sales, marketing and development projects. In
addition, during the first quarter of fiscal year 2008, we raised additional
capital through a private equity financing and by the sale of our facility under
a leaseback agreement.
o On June 21, 2007, we entered into a Securities Purchase Agreement with
Kerns Manufacturing Corp. (Kerns). Concurrently with our entry into
the Securities Purchase Agreement, we also entered into a Distribution
Agreement and a Supplier Agreement with Living Data Technology
Corporation (Living Data), an affiliate of Kerns.
We sold to Kerns, pursuant to the Securities Purchase Agreement,
21,428,572 shares of our common stock at $.07 per share for an
aggregate of $1,500,000, as well as a five-year warrant to purchase
4,285,714 shares of our common stock at an initial exercise price of
$.08 per share (the Warrant). The agreement further provided for the
appointment to our Board of Directors of two representatives of Kerns.
In furtherance thereof, Jun Ma and Simon Srybnik, Chairman of both
Kerns and Living Data, have been appointed members of our Board of
Directors. Pursuant to the Distribution Agreement, we have become the
exclusive distributor in the United States of the AngioNew ECP systems
manufactured by Living Data. As additional consideration for such
agreement, we agreed to issue an additional 6,990,840 shares of our
common stock to Living Data. Pursuant to the Supplier Agreement,
Living Data now is the exclusive supplier to us of the ECP therapy
systems that we market under the registered trademark EECP(R). The
Distribution Agreement and the Supplier Agreement each have an initial
term extending through May 31, 2012.
Page 7
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited)
August 31, 2008
Pursuant to a Registration Rights Agreement, we granted to Kerns and
Living Data, subject to certain restrictions, "piggyback registration
rights" covering the shares sold to Kerns as well as the shares
issuable upon exercise of the Warrant and the shares issued to Living
Data.
o On August 15, 2007, we sold our facility under a five-year leaseback
agreement for $1.4 million. The net proceeds from the sale were
approximately $425,000, after payment in full of the two secured notes
on our facility, brokers fees, closing costs, and the opening of a
certificate of deposit in accordance with the provisions of the new
lease.
NOTE B - STOCK-BASED COMPENSATION
As of June 1, 2006, the Company adopted Statement of Financial Standards
No. 123 (revised 2004), Share-Based Payment ("SFAS No. 123 (R)"), which is a
revision of SFAS No. 123. SFAS No. 123 (R) supersedes APB Opinion No. 25,
Accounting for Stock Issued to Employees, and amends FASB Statement No. 95,
Statement of Cash Flows.
Generally, the approach to accounting for share-based payments in SFAS No.
123(R) is similar to the approach described in SFAS No. 123. However, SFAS No.
123(R) requires all share-based payments to employees, including grants of
employee stock options, to be recognized in the financial statements based on
their fair values. Pro forma disclosure of the fair value of share-based
payments is no longer an alternative to financial statement recognition.
During the three-month period ended August 31, 2008, the Board of Directors
did not grant any non-qualified stock options.
During the three-month period ended August 31, 2008, the Company's Board of
Directors granted 150,000 shares of common stock to one employee of the Company
having a fair market value of $0.08 per share at the time of the respective
grant, but was not issued until the second quarter of fiscal 2009.
Stock-based compensation expense recognized under SFAS 123(R) was $5,314
and $61,786 for the three months ended August 31, 2008 and 2007, respectively.
For purposes of estimating the fair value of each option on the date of grant,
the Company utilized the Black-Scholes option-pricing model. The Black-Scholes
option valuation model was developed for use in estimating the fair value of
traded options, which have no vesting restrictions and are fully transferable.
In addition, option valuation models require the input of highly subjective
assumptions including the expected stock price volatility. Because the Company's
employee stock options have characteristics significantly different from those
of traded options and because changes in the subjective input assumptions can
materially affect the fair value estimate, in management's opinion, the existing
models do not necessarily provide a reliable single measure of the fair value of
its employee stock options.
Equity instruments issued to non-employees in exchange for goods, fees and
services are accounted for under the fair value-based method of SFAS No. 123(R).
Page 8
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited)
August 31, 2008
The fair value of the Company's stock-based awards was estimated assuming
the following weighted-average assumptions:
Expected life (years) 5
Expected volatility 93%
Risk-free interest rate 5%
Expected dividend yield 0%
NOTE C -LOSS PER COMMON SHARE
The following table sets forth the computation of basic and diluted loss
per share:
Three months ended August 31,
---------------------------------------
2008 2007
----------------- -----------------
Numerator:
Net loss $ (549,971) $ (18,876)
Denominator:
Basic - weighted average common shares 93,768,004 87,748,778
Stock options -
Warrants -
----------------- -----------------
Diluted - weighted average common shares 93,768,004 87,748,778
================= =================
Loss per share - basic $ (0.01) $ (0.00)
================= =================
- diluted $ (0.01) $ (0.00)
================= =================
Options and warrants, in accordance with the following table, were excluded
from the computation of diluted loss per share for the three months ended August
31, 2008 and 2007, because the effect of their inclusion would be antidilutive.
Three months ended August 31,
----------------------------------------
2008 2007
--------------- -----------------
Options 5,460,210 5,996,710
Warrants 6,540,252 6,540,252
------------------ -----------------
12,000,462 12,536,962
================== =================
Page 9
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited)
August 31, 2008
NOTE D - INVENTORIES, NET
Inventories, net of reserves consist of the following:
August 31, 2008 May 31, 2008
------------------ ------------------
Raw materials $ 947,759 $ 936,035
Work in process 491,602 603,925
Finished goods 387,084 112,718
------------------ ------------------
$ 1,826,445 $ 1,652,678
================== ==================
At August 31, 2008 and May 31, 2008, the Company had reserves for excess
and obsolete inventory of $581,725 and $594,042, respectively.
NOTE E - PROPERTY AND EQUIPMENT
Property and equipment is summarized as follows:
August 31, 2008 May 31, 2008
------------------ ------------------
Office, laboratory and other equipment $ 1,230,771 $ 1,368,170
EECP(R) systems under operating leases
or under loan for clinical trials 738,674 719,401
Furniture and fixtures 148,165 148,165
------------------ ------------------
2,117,610 2,235,736
Less: accumulated depreciation 2,057,558 2,178,566
------------------ ------------------
Property and equipment - net $ 60,052 $ 57,170
================== ==================
Depreciation expense amounted to $17,772 and $58,734 for the three-month
periods ended August 31, 2008 and 2007, respectively.
NOTE F - DEFERRED REVENUE
Page 10
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited)
August 31, 2008
The changes in the Company's deferred revenues are as follows:
Three Months Ended August 31,
---------------------------------------------
2008 2007
-------------------- --------------------
Deferred revenue at the beginning of the period $ 1,618,053 $ 1,756,352
Additions:
Deferred extended service contracts 446,834 411,900
Deferred in-service and training 17,500 10,000
Deferred service arrangements 600 4,500
Deferred service arrangement obligations 52,500 50,000
Recognized as revenue:
Deferred extended service contracts (410,126) (566,004)
Deferred in-service and training (12,500) (7,500)
Deferred service arrangements (600) (3,450)
Deferred service arrangement obligations (49,579) (36,167)
-------------------- --------------------
Deferred revenue at end of period 1,662,682 1,619,631
Less: current portion 1,151,556 1,244,920
-------------------- --------------------
Long-term deferred revenue at end of period $ 511,126 $ 374,711
==================== ====================
NOTE G - SALE-LEASEBACK
In August 2007, the Company sold its warehouse and corporate facility for
$1,400,000. Under the agreement, the Company is leasing back the property from
the purchaser over a period of five years. The Company is accounting for the
leaseback as an operating lease. The gain of $266,226 realized in this
transaction has been deferred and is being amortized to income ratably over the
term of the lease. At August 31, 2008, the unamortized deferred gain of $208,544
is shown as "Deferred gain on sale of building" in the Company's consolidated
condensed balance sheet. The short-term portion of $53,245 is shown in current
liabilities and the long-term portion of $155,299 is in long-term liabilities.
The amount recognized as a gain in the first quarter of fiscal 2008 was $13,311.
NOTE H - WARRANTY LIABILITY
The changes in the Company's product warranty liability are as follows:
August 31, 2008 August 31, 2007
-------------------- --------------------
Warranty liability at the beginning of the period $ 17,250 $ 15,750
Expense for new warranties issued 18,000 9,000
Warranty claims (11,750) (9,500)
-------------------- --------------------
Warranty liability at the end of the year 23,500 15,250
-------------------- --------------------
Long-term warranty liability at the end of the year $ - $ -
==================== ====================
NOTE I - RELATED-PARTY TRANSACTIONS
On June 21, 2007, we entered into a Securities Purchase Agreement with
Kerns. Concurrently with our entry into the Securities Purchase Agreement, we
also entered into a Distribution Agreement and a Supplier Agreement with Living
Data, an affiliate of Kerns.
Page 11
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited)
August 31, 2008
We sold to Kerns, pursuant to the Securities Purchase Agreement, 21,428,572
shares of our common stock at $.07 per share for an aggregate of $1,500,000, as
well a five-year warrant to purchase 4,285,714 shares of our common stock at an
initial exercise price of $.08 per share (the "Warrant"). The agreement further
provided for the appointment to our Board of Directors of two representatives of
Kerns. In furtherance thereof, Jun Ma and Simon Srybnik, Chairman of both Kerns
and Living Data, have been appointed members of our Board of Directors. Pursuant
to the Distribution Agreement, we have become the exclusive distributor in the
United States of the AngioNew ECP systems manufactured by Living Data. As
additional consideration for such agreement, we agreed to issue an additional
6,990,840 shares of our common stock to Living Data. Pursuant to the Supplier
Agreement, Living Data now is the exclusive supplier to us of the ECP therapy
systems that we market under the registered trademark EECP(R). The Distribution
Agreement and the Supplier Agreement each have an initial term extending through
May 31, 2012.
Pursuant to a Registration Rights Agreement, we granted to Kerns and Living
Data, subject to certain restrictions, "piggyback registration rights" covering
the shares sold to Kerns as well as the shares issuable upon exercise of the
Warrant and the shares issued to Living Data.
On July 10, 2007, the Board of Directors appointed Behnam Movaseghi,
Treasurer and Chief Financial Officer of Kerns Manufacturing Corporation, to our
Board of Directors.
As affiliates of Living Data and Kerns, Mr. Ma, Mr. Movaseghi and Mr.
Srybnik have each been directly involved in the transactions between Living Data
or Kerns, on the one hand, and the Company, on the other hand, with respect to
the Securities Purchase Agreement, the Distribution Agreement and the Supplier
Agreement, as well as providing consulting services to the Company without
compensation.
During the three-month period ended August 31, 2008, the Company purchased
ECP therapy systems under the Supplier Agreement for $75,000 from Living Data.
In addition, Living Data purchased $3,162 worth of ECP therapy system components
from the Company.
During the three-month period ended August 31, 2008, Living Data assigned
to the Company all of its rights and interests under its Distributorship
Agreement with a corporation organized and existing under the laws of the
People's Republic of China that manufactures Ambulatory Blood Pressure Monitors,
Ambulatory ECG Recorders and Holter & ABPM Combiner Recorders, for $20,000
payable to Living Data based on certain terms and conditions. The Company has
also agreed to pay to Living Data 5% of the selling price or 5% of the cost of
all goods sold (whichever is higher), and 5% of the cost of all goods
transferred but not sold under the Assignment Agreement to Living Data based on
sales of this equipment. The Company intends to sell these systems in the United
States and other countries subject to obtaining regulatory clearance.
During the three-month period ended August 31, 2008, Living Data assigned
to the Company all of its rights and interests under its Distributorship
Agreement with a corporation organized and existing under the laws of the
People's Republic of China that manufactures Ultrasound Scanners, for $20,000
payable to Living Data based on certain terms and conditions. The Company has
also agreed to pay to Living Data 5% of the selling price or 5% of the cost of
all goods sold (whichever is higher), and 5% of the cost of all goods
transferred but not sold under the Assignment Agreement to Living Data based on
sales of this equipment. The Company intends to sell these systems in the United
States and other countries subject to obtaining regulatory clearance.
In July of 2008, the Company agreed to purchase ECP therapy systems under
its Distributorship Agreement with Living Data for $360,000 payable over 18
months. The current portion of the outstanding liability as of August 31, 2008
in the amount of $240,000 is reflected in accounts payable and accrued expenses
and the remaining balance of $80,000 is reflected in long-term liabilities on
the accompanying balance sheet.
Further, Kerns provides the Company, free of charge, part-time use of one
of its Information Technology (IT) employees as well one of their IT consultants
to provide the Company with IT and database support services. In addition, a
Page 12
Vasomedical, Inc. and Subsidiaries
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (unaudited)
August 31, 2008
clinical applications support specialist and a service engineer from Living Data
may be used by the Company to provide customers with clinical training and
technical service. The Company was charged $2,100 for the services of the
clinical applications support specialist and $1,350 for the services of the
service engineer during the three-month period ended August 31, 2008.
NOTE J - INCOME TAXES
During the three-months ended August 31, 2008 and August 31, 2007, state
income taxes were $3,750 and $6,296, respectively.
As of August 31, 2008, the recorded deferred tax assets were $20,001,852,
reflecting a $182,500 increase during the first quarter of fiscal 2009. The
deferred tax assets were offset by a valuation allowance of the same amount.
Ultimate realization of any or all of the deferred tax assets is not assured,
due to significant uncertainties and material assumptions associated with
estimates of future taxable income during the carryforward period. The Company
has concluded that, based upon the weight of available evidence, it was "more
likely than not" that the net deferred tax asset would not be realized.
NOTE K - COMMITMENTS AND CONTINGENCIES
Leases
On August 15, 2007, we sold our facility under a five-year leaseback
agreement. Future rental payments under the operating lease are as follows:
For the years ended:
May 31, 2009 $ 108,122
May 31, 2010 148,488
May 31, 2011 154,427
May 31, 2012 160,604
May 31, 2013 40,541
------------------
Total $ 612,182
==================
Litigation
The Company is currently, and has been in the past, a party to various
routine legal proceedings incident to the ordinary course of business. The
Company believes that the outcome of all such pending legal proceedings in the
aggregate is unlikely to have a material adverse effect on the business or
consolidated condensed financial condition of the Company.
NOTE L - SUBSEQUENT EVENT
On September 9, 2008, the Company's Board of Directors granted, but have
not issued as of yet, 2,025,000 shares of our common stock for fiscal 2008
compensation to the Company's board members, having a fair market value of $0.06
per share at the time of the respective grant. The total amount charged to
compensation expense, for this grant, at August 31, 2008 amounted to $121,500
with the corresponding liability reflected on the balance sheet in accounts
payable and accrued expenses.
Page 13
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Except for historical information contained in this report, the matters
discussed are forward-looking statements that involve risks and uncertainties.
When used in this report, words such as "anticipates", "believes", "could",
"estimates", "expects", "may", "plans", "potential" and "intends" and similar
expressions, as they relate to the Company or its management, identify
forward-looking statements. Such forward-looking statements are based on the
beliefs of the Company's management, as well as assumptions made by and
information currently available to the Company's management. Among the factors
that could cause actual results to differ materially are the following: the
effect of business and economic conditions; the effect of the dramatic changes
taking place in the healthcare environment; the impact of competitive procedures
and products and their pricing; medical insurance reimbursement policies;
unexpected manufacturing or supplier problems; unforeseen difficulties and
delays in the conduct of clinical trials and other product development programs;
the actions of regulatory authorities and third-party payers in the United
States and overseas; uncertainties about the acceptance of a novel therapeutic
modality by the medical community; and the risk factors reported from time to
time in the Company's SEC reports. The Company undertakes no obligation to
update forward-looking statements as a result of future events or developments.
General Overview
Vasomedical, Inc. was incorporated in Delaware in July 1987. Unless the
context requires otherwise, all references to "we", "our", "us", "Company",
"registrant", "Vasomedical" or "management" refer to Vasomedical, Inc. and its
subsidiaries. Since 1995, we have been primarily engaged in designing,
manufacturing, marketing and supporting EECP(R) enhanced external
counterpulsation systems based on our unique proprietary technology currently
indicated for use in cases of stable or unstable angina (i.e., chest pain),
congestive heart failure (CHF), acute myocardial infarction (i.e., heart attack,
(MI)) and cardiogenic shock. The EECP(R) therapy system is a non-invasive,
outpatient therapy for the treatment of diseases of the cardiovascular system.
The therapy serves to increase circulation in areas of the heart with less than
adequate blood supply and helps to restore systemic vascular function. The
therapy also increases blood flow and oxygen supply to the heart muscle and
other organs and decreases the heart's workload and reduces oxygen demand, while
also improving function of the endothelium, the lining of blood vessels
throughout the body, lessening resistance to blood flow. We provide hospitals,
clinics and physician private practices with EECP(R) equipment, treatment
guidance, and a staff training and equipment maintenance program designed to
provide optimal patient outcomes. EECP(R) is a registered trademark for
Vasomedical's enhanced external counterpulsation therapy and systems. For more
information, visit www.vasomedical.com.
We have FDA clearance to market our EECP(R) therapy for use in the
treatment of stable and unstable angina, congestive heart failure, acute
myocardial infarction, and cardiogenic shock; however, our current marketing
efforts are limited to the treatment of chronic stable angina and congestive
heart failure. Medicare and other third-party payers currently reimburse for the
treatment of angina pectoris patients with moderate to severe symptoms who are
refractory to medications and not candidates for invasive procedures. Patients
with co-morbidities of heart failure, diabetes, peripheral vascular disease,
etc. are also reimbursed under the same criteria, provided the primary diagnosis
and indication for treatment with EECP(R) therapy is angina symptoms.
During the last several years, we incurred operating losses. We have
attempted to achieve profitability by reducing operating costs and halting the
trend of declining revenue, and to reduce cash usage through bringing our cost
structure more into alignment with current revenues. By engaging in
restructurings during March 2007 and April 2007, the Company has substantially
reduced personnel and spending on sales, marketing and development projects. In
addition, during the first quarter of fiscal year 2008, we raised additional
capital through a private equity financing and by the sale of our facility under
a leaseback agreement. See Note A for details of these events.
Page 14
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Market Overview
Cardiovascular disease (CVD) is the leading cause of death in the world and
is among the top three diseases in terms of healthcare spending in nearly every
country. CVD claimed approximately 2.4 million lives in the United States in
2003 and was responsible for 1 of every 2.7 deaths, according to The American
Heart Association (AHA) Heart and Stroke Statistical 2006 Update (2006 Update).
Approximately 71.3 million Americans suffer from some form of cardiovascular
disease. Among these, 12.0 million have coronary heart disease (CHD).
We have FDA clearance to market our EECP(R) therapy for use in the
treatment of stable and unstable angina, congestive heart failure, acute
myocardial infarction, and cardiogenic shock; however, our current marketing
efforts are limited to the treatment of chronic stable angina and congestive
heart failure. Medicare and other third-party payers currently reimburse for the
treatment of angina pectoris patients with moderate to severe symptoms who are
refractory to medications and not candidates for invasive procedures. Patients
with co-morbidities of heart failure, diabetes, peripheral vascular disease,
etc. are also reimbursed under the same criteria, provided the primary diagnosis
and indication for treatment with EECP(R) therapy is refractory angina symptoms.
We will continue to educate the marketplace that EECP(R) therapy is a
therapy for ischemic cardiovascular disease and that patients with a primary
diagnosis of heart failure, diabetes or peripheral vascular disease are also
eligible for reimbursement under the current coverage policy, provided the
primary indication for treatment with EECP(R) therapy is refractory angina or
angina equivalent symptoms and the patient satisfies other listed criteria.
Additionally, we will continue to pursue expansion of coverage for EECP(R)
therapy with Medicare and other third-party payers as evidence of its clinical
utility develops.
Angina
Angina pectoris is the medical term for a recurring pain or discomfort in
the chest due to coronary artery disease (CAD). Angina is a symptom of a
condition called myocardial ischemia, which occurs when the heart muscle or
myocardium doesn't receive sufficient blood, hence as much oxygen, as it needs.
This usually happens because one or more of the heart's arteries, the blood
vessels that supply blood to the heart muscle, is narrow or blocked.
Insufficient blood supply to meet the need of the organ to function is called
ischemia.
The cardinal symptom of stable CAD is anginal chest pain or equivalent
symptoms, such as exertional dyspnea or fatigue. Angina is uncomfortable
pressure, fullness, squeezing or pain, usually occurring in the center of the
chest under the breastbone. The discomfort also may be felt in the neck, jaw,
shoulder, back or arm. Often the patient suffers not only from the discomfort of
the symptom itself but also from the accompanying limitations on activities and
the associated anxiety that the symptoms may produce. Uncertainty about
prognosis may be an additional source of anxiety. For some patients, the
predominant symptoms may be palpitations or syncope that is caused by
arrhythmias or fatigue, edema, or orthopnea caused by heart failure. Episodes of
angina occur when the heart's need for oxygen increases beyond the oxygen
available from the blood nourishing the heart. Physical exertion is the most
common trigger, but not the only one for angina. For example, running to catch a
bus could trigger an attack of angina while walking might not. Angina may happen
during exercise, periods of emotional stress, exposure to extreme cold or heat,
heavy meals, alcohol consumption or cigarette smoking. Some people, such as
those with a coronary artery spasm, may have angina when they are resting.
There are approximately 6.4 million angina patients in the United States
and our EECP(R) therapy currently competes with other technologies in the market
for approximately 100,000 to 150,000 new refractory angina patients annually who
do not adequately respond to or are not amenable to medical and surgical therapy
and have the potential to meet the guidelines for reimbursement of EECP(R)
therapy. Most angina patients are treated with medications, including beta
blockers to slow and protect the heart, and vasodilators which are often
prescribed to increase blood flow to the coronary arteries. When drugs fail or
inadequately correct the problem, the patients are considered unresponsive to
medical therapy. Most angina patients are readily amenable to invasive
Page 15
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
revascularization procedures such as angioplasty and coronary stent placement,
as well as coronary artery bypass grafting (CABG). However, there are
approximately 100,000 to 150,000 angina patients each year whose angina can not
be stopped by medication and they are no longer readily amenable to palliative
invasive procedures.
In February 1999, the Centers for Medicare and Medicaid Services (CMS), the
federal agency that administers the Medicare program for more than 39 million
beneficiaries, issued a national coverage policy for the use of external
counterpulsation therapy in the treatment of refractory angina. Medicare
reimbursement guidelines have a significant impact in determining the available
market for EECP(R) therapy. We believe that over 65% of the patients that
receive EECP(R) therapy are Medicare patients and many of the third-party payers
follow Medicare guidelines, which limit reimbursement for EECP(R) therapy to
patients who do not adequately respond to or are not amenable to medical therapy
and are not readily amenable to invasive therapy. As a result, an important
element of our strategy is to grow the market for EECP(R) therapy by expanding
reimbursement coverage to include a broader range of angina patients than the
current coverage policy provides and enable EECP(R) therapy to compete more with
other therapies for ischemic heart disease. Please see the heading
"Reimbursement" in the "Item-1 Business" section of this Form 10-KSB for a more
detailed discussion of reimbursement issues.
Congestive Heart Failure (CHF)
CHF is a condition in which the heart loses its pumping capacity to supply
the metabolic needs of all other organs. The condition affects both sexes and is
most common in people over age 50. Symptoms include angina, shortness of breath,
weakness, fatigue, swelling of the abdomen, legs and ankles, rapid or irregular
heartbeat and low blood pressure. Causes range from chronic high blood pressure,
heart-valve disease, heart attack, coronary artery disease, heartbeat
irregularities, severe lung disease such as emphysema, congenital disease,
cardiomyopathy, hyperthyroidism, severe anemia and others.
CHF is treated with medication and, sometimes, surgery on heart valves or
the coronary arteries and, in certain severe cases, heart transplants. Left
ventricular assist devices (LVADs) and the use of cardiac resynchronization and
implantable defibrillators are useful in selected patients with heart failure.
Still, no consensus therapy currently exists for CHF and patients must currently
suffer their symptoms chronically and have a reduced life expectancy.
According to the 2006 Update, in 2003 approximately 2.4 million men and 2.6
million women in the United States had CHF and about 550,000 new cases of the
disease occur each year. Deaths caused by the disease increased 20.5% from 1993
to 2003. The prevalence of the disease is growing as a result of the aging of
the population and the improved survival rate of people after heart attacks.
Because the condition frequently entails visits to the emergency room and
in-patient treatment centers, two-thirds of all hospitalizations for people over
age 65 are due to CHF. The economic burden of congestive heart failure is
enormous with an estimated cost to the health care system in 2005 in the United
States of $29.6 billion. Congestive heart failure offers a good strategic fit
with our current angina business and offers an expanded market opportunity for
EECP(R) therapy. Unmet clinical needs in CHF are greater than those for angina,
as there are few consensus therapies, invasive or otherwise, beyond medical
management for the condition. It is noteworthy that data collected from the
International EECP(R) Patient Registry(TM) (IEPR) at the University of
Pittsburgh Graduate School of Public Health shows that approximately one-third
of angina patients treated with EECP(R) also have a history of CHF and 70% to
80% have demonstrated positive outcomes from EECP(R) therapy.
We sponsored a pivotal, randomized clinical trial to demonstrate the
efficacy of EECP(R) therapy in the most prevalent types of heart failure
patients. This trial, known as PEECH(TM) (Prospective Evaluation of EECP(R) in
Congestive Heart Failure), was intended to provide additional evidence of the
safety and efficacy of EECP(R) therapy in the treatment of mild-to-moderate
heart failure and to support our application for expansion of the Medicare
national reimbursement coverage policy to include mild-to-moderate heart failure
as a primary indication. The PEECH(TM) trial was a positive clinical trial,
having met the statistical requirement of meeting at least one of its co-primary
endpoints, a significant difference in the proportion of patients satisfying a
Page 16
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
prespecified threshold of improvement in exercise duration. The trial also
demonstrated significant improvements in favor of EECP(R) therapy on several
important secondary endpoints, including exercise duration and improvement in
symptom status and quality of life. Measures of change in peak oxygen
consumption were not statistically significant in the overall study population,
though a trend favoring EECP(R) therapy was present in early follow-up. Patients
in the trial who had an ischemic etiology (i.e. pre-existing coronary artery
disease), demonstrated a greater response to EECP(R) therapy than those who had
an idiopathic (non-ischemic) etiology.
The preliminary results of the PEECH(TM) trial were presented at the
American College of Cardiology scientific sessions in March 2005. On June 20,
2005, CMS accepted our application for expansion of reimbursement coverage of
EECP(R) therapy to include patients with New York Heart Association (NYHA) Class
II/III stable heart failure symptoms with an ejection fraction of less than or
equal to 35% (i.e. chronic, stable, mild-to-moderate systolic heart failure as a
primary indication), as well as patients with Canadian Cardiovascular Society
Classification (CCSC) II (i.e. chronic, stable mild angina).
On June 23, 2005, CMS also received a request from a competing manufacturer
of external counterpulsation therapy equipment to reconsider the reimbursement
coverage policy. They requested expansion of coverage to include 1) treatment of
congestive heart failure, to include NYHA Class II, III with a left ventricular
ejection fraction (LVEF) less than or equal to 40%, and acute heart failure; 2)
treatment of stable angina to include CCSC II angina; 3) treatment of acute
myocardial infarction; and 4) treatment of cardiogenic shock. On September 15,
2005, the competing manufacturer also amended their request to include NYHA
Class IV heart failure.
On March 20, 2006, CMS issued their Decision Memorandum regarding this
reconsideration with the opinion "that the evidence is not adequate to conclude
that external counterpulsation therapy is reasonable and necessary for the
treatment of:
o CCSC II angina
o Heart Failure
0 NYHA Class II/III stable heart failure symptoms with an ejection
fraction of less than or equal to 35%
0 NYHA Class II/III stable heart failure symptoms with an ejection
fraction of less than or equal to 40%
0 NYHA Class IV heart failure
0 Acute heart failure
o Cardiogenic shock
o Acute myocardial infarction."
They did, however, reiterate in the decision memorandum that "Current
coverage as described in Section 20.20 of the Medicare National Coverage
Determination (NCD) manual will remain in effect" for refractory angina
patients.
On August 25, 2006 the results of the trial were initially published online
by the Journal of the American College of Cardiology (JACC) and in print in its
September 19, 2006 issue. JACC is the official journal of the American College
of Cardiology.
In the November-December issue of the journal Congestive Heart Failure, a
second report of results from the PEECH(TM) trial was published, focusing on the
results of a prespecified subgroup analysis in trial patients age 65 and over.
This analysis demonstrated a statistically positive response on both co-primary
endpoints of the trial in patients receiving EECP(R) therapy versus those who
did not, i.e. a significantly larger proportion of patients undergoing EECP(R)
Page 17
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
therapy met or exceeded prespecified thresholds of improvement in exercise
duration and peak oxygen consumption. Moreover, the patients age 65 and older
who received EECP(R) therapy demonstrated the greatest differences in exercise
duration, peak oxygen consumption and functional class (symptom status) compared
with those who did not receive EECP(R) therapy.
These papers were submitted to CMS and we were advised to continue to
gather more clinical evidence for future submission.
We will continue to educate the marketplace that EECP(R) therapy is a
therapy for ischemic cardiovascular disease and that patients with a primary
diagnosis of heart failure, diabetes, peripheral vascular disease, etc. are also
eligible for reimbursement under the current coverage policy, provided the
primary indication for treatment with EECP(R) therapy is refractory angina or
angina equivalent symptoms and the patient satisfies other listed criteria.
Additionally, we will continue to pursue expansion of coverage for EECP(R)
therapy with Medicare and other third-party payers as evidence of its clinical
utility develops.
Critical Accounting Policies
Financial Reporting Release No. 60, which was released by the Securities
and Exchange Commission, (SEC), in December 2001, requires all companies to
include a discussion of critical accounting policies or methods used in the
preparation of financial statements. Note B of the Notes to Consolidated
Condensed Financial Statements included in our Annual Report on Form 10-KSB for
the year ended May 31, 2008, includes a summary of our significant accounting
policies and methods used in the preparation of our financial statements. In
preparing these financial statements, we have made our best estimates and
judgments of certain amounts included in the financial statements, giving due
consideration to materiality. The application of these accounting policies
involves the exercise of judgment and use of assumptions as to future
uncertainties and, as a result, actual results could differ from these
estimates. Our critical accounting policies are as follows:
Revenue Recognition
The Company recognizes revenue when persuasive evidence of an arrangement
exists, delivery has occurred or service has been rendered, the price is fixed
or determinable and collectibility is reasonably assured. In the United States,
we recognize revenue from the sale of our EECP(R) systems in the period in which
we deliver the system to the customer. Revenue from the sale of our EECP(R)
systems to international markets is recognized upon shipment of the product to a
common carrier, as are supplies, accessories and spare parts delivered to both
domestic and international customers. Returns are accepted prior to the
in-service and training subject to a 10% restocking charge or for normal
warranty matters, and we are not obligated for post-sale upgrades to these
systems. In addition, we use the installment method to record revenue based on
cash receipts in situations where the account receivable is collected over an
extended period of time and in our judgment the degree of collectibility is
uncertain.
In most cases, revenue from domestic EECP(R) system sales is generated from
multiple-element arrangements that require judgment in the areas of customer
acceptance, collectibility, the separability of units of accounting, and the
fair value of individual elements. We follow the provisions of Emerging Issues
Task Force, or EITF, Issue No. 00-21, "Revenue Arrangements with Multiple
Deliverables" ("EITF 00-21"). The principles and guidance outlined in EITF 00-21
provide a framework to determine (a) how the arrangement consideration should be
measured (b) whether the arrangement should be divided into separate units of
accounting, and (c) how the arrangement consideration should be allocated among
the separate units of accounting. We determined that the domestic sale of our
EECP(R) systems includes a combination of three elements that qualify as
separate units of accounting:
i. EECP(R) equipment sale,
ii. provision of in-service and training support consisting of equipment
set-up and training provided at the customer's facilities, and
iii. a service arrangement (usually one year), consisting of: service by
factory-trained service representatives, material and labor costs,
emergency and remedial service visits, software upgrades, technical
phone support and preferred response times.
Page 18
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Each of these elements represent individual units of accounting as the
delivered item has value to a customer on a stand-alone basis, objective and
reliable evidence of fair value exists for undelivered items, and arrangements
normally do not contain a general right of return relative to the delivered
item. We determine fair value based on the price of the deliverable when it is
sold separately or based on third-party evidence. In accordance with the
guidance in EITF 00-21, we use the residual method to allocate the arrangement
consideration when it does not have fair value of the EECP(R) system sale. Under
the residual method, the amount of consideration allocated to the delivered item
equals the total arrangement consideration less the aggregate fair value of the
undelivered items. Assuming all other criteria for revenue recognition have been
met, we recognize revenue for:
i. EECP(R) equipment sales, when delivery and acceptance occurs based on
delivery and acceptance documentation received from independent
shipping companies or customers,
ii. in-service and training, following documented completion of the
training, and
iii. the service arrangement, ratably over the service period, which is
generally one year.
In-service and training generally occurs within a few weeks of shipment and
our return policy states that no returns will be accepted after in-service and
training has been completed. The amount related to in-service and training is
recognized as service revenue at the time the in-service and training is
completed and the amount related to service arrangements is recognized ratably
as service revenue over the related service period, which is generally one year.
Costs associated with the provision of in-service and training and the service
arrangement, including salaries, benefits, travel, spare parts and equipment,
are recognized in cost of equipment sales as incurred.
The Company also recognizes revenue generated from servicing EECP(R)
systems that are no longer covered by the service arrangement, or by providing
sites with additional training, in the period that these services are provided.
Revenue related to future commitments under separately priced extended service
agreements on our EECP(R) system are deferred and recognized ratably over the
service period, generally ranging from one year to four years. Costs associated
with the provision of service and maintenance, including salaries, benefits,
travel, spare parts and equipment, are recognized in cost of sales as incurred.
Amounts billed in excess of revenue recognized are included as deferred revenue
in the consolidated condensed balance sheets.
Revenues from the sale of EECP(R) systems through our international
distributor network are generally covered by a one-year warranty period. For
these customers we accrue a warranty reserve for estimated costs to provide
warranty parts when the equipment sale is recognized. . The Company has also
entered into lease agreements for our EECP(R) systems, generally for terms of
one year or less, that are classified as operating leases. Revenues from
operating leases are generally recognized, in accordance with the terms of the
lease agreements, on a straight-line basis over the life of the respective
leases. For certain operating leases in which payment terms are determined on a
"fee-per-use" basis, revenues are recognized as incurred (i.e., as actual usage
occurs). The cost of the EECP(R) system utilized under operating leases is
recorded as a component of property and equipment and is amortized to cost of
sales over the estimated useful life of the equipment, not to exceed five years.
There were no significant minimum rental commitments on these operating leases
at August 31, 2008.
Accounts Receivable, net
The Company's accounts receivable are due from customers engaged in the
provision of medical services. Credit is extended based on evaluation of a
customer's financial condition and, generally, collateral is not required.
Accounts receivable are generally due 30 to 90 days from shipment and are stated
at amounts due from customers net of allowances for doubtful accounts, returns,
term discounts and other allowances. Accounts that remain outstanding longer
than the contractual payment terms are considered past due. Estimates are used
in determining the allowance for doubtful accounts based on the Company's
historical collections experience, current trends, credit policy and a
percentage of its accounts receivable by aging category. In determining these
Page 19
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
percentages, we look at historical write-offs of our receivables. The Company
also looks at the credit quality of its customer base as well as changes in its
credit policies. The Company continuously monitors collections and payments from
our customers. While credit losses have historically been within expectations
and the provisions established, the Company cannot guarantee that it will
continue to experience the same credit loss rates that it has in the past.
Inventories, net
The Company values inventory at the lower of cost or estimated market, cost
being determined on a first-in, first-out basis. The Company often places
EECP(R) systems at various field locations for demonstration, training,
evaluation, and other similar purposes at no charge. The cost of these EECP(R)
systems is transferred to property and equipment and is amortized over the next
two to five years. The Company records the cost of refurbished components of
EECP(R) systems and critical components at cost plus the cost of refurbishment.
The Company regularly reviews inventory quantities on hand, particularly raw
materials and components, and records a provision for excess and obsolete
inventory based primarily on existing and anticipated design and engineering
changes to its products as well as forecasts of future product demand.
We have adopted the provisions of Statement of Financial Accounting
Standards No. 151, "Inventory Costs", on a prospective basis. The statement
clarifies that abnormal amounts of idle facility expense, freight, handling
costs, and wasted materials (spoilage) should be recognized as current-period
charges and requires the allocation of fixed production overheads to inventory
based on the normal capacity of the production facilities. As a result of
adopting SFAS No. 151, we absorbed approximately $36,000 more in fixed
production overhead into inventory during the first quarter of fiscal year 2009
as compared to the same period in fiscal 2008.
Deferred Revenues
The Company records revenue on extended service contracts ratably over the
term of the related contract period. In accordance with the provisions of EITF
00-21, we began to defer revenue related to EECP(R) system sales for the fair
value of installation and in-service training to the period when the services
are rendered and for warranty obligations ratably over the service period, which
is generally one year.
Warranty Costs
Equipment sold is generally covered by a warranty period of one year. Under
the provisions of EITF 00-21, for certain arrangements, a portion of the overall
system price attributable to the first year service arrangement is deferred and
recognized as revenue over the service period. As such, we do not accrue
warranty costs upon delivery but we rather recognize warranty and related
service costs as incurred.
Equipment sold to international customers through our distributor network
is generally covered by a one-year warranty period. For these customers the
Company accrues a warranty reserve for estimated costs of providing a parts only
warranty when the equipment sale is recognized.
The factors affecting our warranty liability included the number of units
sold and historical and anticipated rates of claims and costs per claim.
Net Loss per Common Share
Basic loss per share is based on the weighted average number of common
shares outstanding without consideration of potential common stock. Diluted loss
per share is based on the weighted number of common and potential dilutive
common shares outstanding. The calculation takes into account the shares that
may be issued upon the exercise of stock options and warrants, reduced by the
shares that may be repurchased with the funds received from the exercise, based
on the average price during the period.
Page 20
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Income Taxes
Deferred income taxes are recognized for temporary differences between
financial statement and income tax bases of assets and liabilities and loss
carryforwards for which income tax benefits are expected to be realized in
future years. A valuation allowance is established, when necessary, to reduce
deferred tax assets to the amount expected to be realized. In estimating future
tax consequences, we generally consider all expected future events other than an
enactment of changes in the tax laws or rates. The deferred tax asset is
continually evaluated for realizability. To the extent our judgment regarding
the realization of the deferred tax assets changes, an adjustment to the
allowance is recorded, with an offsetting increase or decrease, as appropriate,
in income tax expense. Such adjustments are recorded in the period in which our
estimate as to the realizability of the asset changed that it is "more likely
than not" that all of the deferred tax assets will be realized. The "more likely
than not" standard is subjective, and is based upon our estimate of a greater
than 50% probability that the deferred tax asset will be realized.
Deferred tax assets and liabilities are classified as current or
non-current based on the classification of the related asset or liability for
financial reporting. A deferred tax asset or liability that is not related to an
asset or liability for financial reporting, including deferred tax assets
related to carryforwards, are classified according to the expected reversal date
of the temporary difference. The deferred tax asset the Company previously
recorded, and then reversed fully in fiscal 2006, related primarily to the
realization of net operating loss carryforwards, of which the allocation of the
current portion, if any, reflected the expected utilization of such net
operating losses for the following twelve months. Such allocation was based on
the Company's internal financial forecast and may be subject to revision based
upon actual results.
Stock-based Employee Compensation
In December 2004, the FASB issued Statement of Financial Standards No. 123
(revised 2004), Share-Based Payment ("SFAS No. 123 (R)"), which is a revision of
SFAS No. 123. SFAS No. 123 (R) supersedes APB Opinion No. 25, Accounting for
Stock Issued to Employees, and amends FASB Statement No. 95, Statement of Cash
Flows. Generally, the approach to accounting for share-based payments in SFAS
No. 123(R) is similar to the approach described in SFAS No. 123. However, SFAS
No. 123(R) requires all share-based payments to employees including grants of
employee stock options, to be recognized in the financial statements based on
their fair values. Pro forma disclosure of the fair value of share-based
payments is no longer an alternative to financial statement recognition. The
Company has five stock-based employee compensation plans.
As new stock options are issued by the Company this may have a material
effect on its quarterly and annual financial statements, in the form of
additional compensation expense. It is not possible to precisely determine the
expense impact of adoption since a portion of the ultimate expense that is
recorded will likely relate to awards that have not yet been granted. The
expense associated with these future awards can only be determined based on
factors such as the price for the Company's common stock, volatility of the
Company's stock price and risk free interest rates as measured at the grant
date.
For purposes of estimating the fair value of each option on the date of
grant, the Company utilizes the Black-Scholes option-pricing model.
The Black-Scholes option valuation model was developed for use in
estimating the fair value of traded options, which have no vesting restrictions
and are fully transferable. In addition, option valuation models require the
input of highly subjective assumptions including the expected stock price
volatility. Because changes in the subjective input assumptions can materially
affect the fair value estimate, in management's opinion, the existing models do
not necessarily provide a reliable measure of the fair value of its employee
stock options.
Page 21
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Equity instruments issued to non-employees in exchange for goods, fees and
services are accounted for under the fair value-based method of SFAS No. 123
(R).
Recently Issued Accounting Pronouncements Not Yet Effective
Statements of Financial Accounting Standards (SFAS):
SFAS No. 141 (R), "Business Combinations" -- retains the fundamental
requirements in Statement 141 that the acquisition method of accounting (which
Statement 141 called the purchase method) be used for all business combinations
and for an acquirer to be identified for each business combination. This
Statement defines the acquirer as the entity that obtains control of one or more
businesses in the business combination and establishes the acquisition date as
the date that the acquirer achieves control.
o replaces Statement 141's cost-allocation process and requires an
acquirer to recognize the assets acquired, the liabilities assumed,
and any noncontrolling interest in the acquiree at the acquisition
date, measured at their fair values as of that date,
o requires the acquirer in a business combination achieved in stages
(sometimes referred to as a step acquisition) to recognize the
identifiable assets and liabilities, as well as the noncontrolling
interest in the acquiree, at the full amounts of their fair values,
o requires that an acquirer evaluate new information and measure a
liability at the higher of its acquisition-date fair value or the
amount that would be recognized if applying Statement 5, then
measuring an asset at the lower of its acquisition-date fair value or
the best estimate of its future settlement amount,
o requires the acquirer to recognize contingent consideration at the
acquisition date, measured at its fair value at that date.
Effective for fiscal years beginning after December 15, 2008
SFAS 157, "Fair Value Measurements" -- defines fair value, establishes a
framework for measuring fair value, and expands disclosures about fair value
measurements. This Statement applies under other accounting pronouncements that
require or permit fair value measurements, where the Board previously concluded
in those accounting pronouncements that fair value is the relevant measurement
attribute. Accordingly, this Statement does not require any new fair value
measurements. However, for some entities, the application of this Statement will
change current practice. This Statement is effective for financial statements
issued for fiscal years beginning after November 15, 2007, and interim periods
within those fiscal years. Earlier application is encouraged, provided that the
reporting entity has not yet issued financial statements for that fiscal year,
including financial statements for an interim period within that fiscal year.
SFAS 159, "The Fair Value Option for Financial Assets and Financial
Liabilities--including an amendment of FASB Statement No. 115" -- permits
entities to choose to measure many financial instruments and certain other items
at fair value. The objective is to improve financial reporting by providing
entities with the opportunity to mitigate volatility in reported earnings caused
by measuring related assets and liabilities differently without having to apply
complex hedge accounting provisions. This Statement is expected to expand the
use of fair value measurement, which is consistent with the Board's long-term
measurement objectives for accounting for financial instruments. This Statement
is effective as of the beginning of an entity's first fiscal year that begins
after November 15, 2007, and interim periods within those fiscal years. Early
adoption is permitted as of the beginning of a fiscal year that begins on or
before November 15, 2007, provided the entity also elects to apply the
provisions of FASB Statement No. 157, "Fair Value Measurements".
Page 22
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
SFAS No. 160, "Noncontrolling Interests in Consolidated Financial
Statements" -- changes the way the consolidated income statement is presented.
It requires consolidated net income to be reported at amounts that include the
amounts attributable to both the parent and the noncontrolling interest. It also
requires disclosure, on the face of the consolidated statement of income, of the
amounts of consolidated net income attributable to the parent and to the
noncontrolling interest. Previously, net income attributable to the
noncontrolling interest generally was reported as an expense or other deduction
in arriving at consolidated net income. It also was often presented in
combination with other financial statement amounts. Effective for fiscal years
beginning after December 15, 2008.
SFAS No. 161, Disclosures about Derivative Instruments and Hedging
Activities - an Amendment of FASB Statement 133 -- enhances required disclosures
regarding derivatives and hedging activities, including enhanced disclosures
regarding how: (a) an entity uses derivative instruments; (b) derivative
instruments and related hedged items are accounted for under FASB Statement No.
133, Accounting for Derivative Instruments and Hedging Activities; and (c)
derivative instruments and related hedged items affect an entity's financial
position, financial performance, and cash flows. Specifically, Statement SFAS
No. 161 requires:
o Disclosure of the objectives for using derivative instruments be
disclosed in terms of underlying risk and accounting designation;
o Disclosure of the fair values of derivative instruments and their
gains and losses in a tabular format;
o Disclosure of information about credit-risk-related contingent
features; and
o Cross-reference from the derivative footnote to other footnotes in
which derivative-related information is disclosed.
Effective for fiscal years and interim periods beginning after November 15,
2008. Early application is encouraged. The Company does not expect that SFAS No.
161 will have any significant effect on future financial statements.
SFAS No. 163, "Accounting for Financial Guarantee Insurance Contracts" --
clarifies how SFAS No. 60, "Accounting and Reporting by Insurance Enterprises",
applies to financial guarantee insurance contracts issued by insurance
enterprises, including the recognition and measurement of premium revenue and
claim liabilities. It also requires expanded disclosures about financial
guarantee insurance contracts. SFAS No. 163 is effective for financial
statements issued for fiscal years beginning after December 15, 2008, and all
interim periods within those fiscal years, except for disclosures about the
insurance enterprise's risk-management activities, which are effective the first
period beginning after May 23, 2008.
FASB Staff Positions (FSP):
FSP APB 14-1, "Accounting for Convertible Debt Instruments That May Be
Settled in Cash upon Conversion (Including Partial Cash Settlement)" --
clarifies that convertible debt instruments that may be settled in cash upon
conversion (including partial cash settlement) are not addressed by paragraph 12
of APB Opinion No. 14, Accounting for Convertible Debt and Debt Issued with
Stock Purchase Warrants. Additionally, this FSP specifies that issuers of such
instruments should separately account for the liability and equity components in
a manner that will reflect the entity's nonconvertible debt borrowing rate when
interest cost is recognized in subsequent periods. This FSP is effective for
financial statements issued for fiscal years beginning after December 15, 2008,
and interim periods within those fiscal years.
FSP FAS 133-1 and FIN 45-4, "Disclosures about Credit Derivatives and
Certain Guarantees: An Amendment of FASB Statement No. 133 and FASB
Interpretation No. 45; and Clarification of the Effective Date of FASB Statement
No. 161" -- amends FASB Statement No. 133, Accounting for Derivative Instruments
and Hedging Activities, to require disclosures by sellers of credit derivatives,
including credit derivatives embedded in a hybrid instrument. This FSP also
amends FASB Interpretation No. 45, Guarantor's Accounting and Disclosure
Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of
Page 23
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Others, to require an additional disclosure about the current status of the
payment/performance risk of a guarantee. Further, this FSP clarifies the Board's
intent about the effective date of FASB Statement No. 161, Disclosures about
Derivative Instruments and Hedging Activities. This FSP is effective for
reporting periods ending after November 15, 2008.
FSP FAS 140-3, "Accounting for Transfers of Financial Assets and Repurchase
Financing Transactions" -- amends FASB Statement 140 to state that a transferor
and transferee shall not separately account for a transfer of a financial asset
and a related repurchase financing unless (a) the two transactions have a valid
and distinct business or economic purpose for being entered into separately and
(b) the repurchase financing does not result in the initial transferor regaining
control over the financial asset. This FSP is effective for financial statements
issued for fiscal years beginning after November 15, 2008, and interim periods
within those fiscal years. Earlier application is not permitted.
FSP FAS 142-3, "Determination of the Useful Life of Intangible Assets" --
amends the factors that should be considered in developing renewal or extension
assumptions used to determine the useful life of a recognized intangible asset
under FASB Statement No. 142, Goodwill and Other Intangible Assets. Paragraph
11(d) of Statement 142 precluded an entity from using its own assumptions about
renewal or extension of an arrangement where there is likely to be substantial
cost or material modifications. This FSP amends paragraph 11(d) of Statement 142
so that an entity will use its own assumptions about renewal or extension of an
arrangement, adjusted for the entity-specific factors in paragraph 11 of
Statement 142, even when there is likely to be substantial cost or material
modifications. Therefore, in determining the useful life of the asset for
amortization purposes, an entity shall consider the period of expected cash
flows used to measure the fair value of the recognized intangible asset,
adjusted for the entity-specific factors including, but are not limited to, the
entity's expected use of the asset and the entity's historical experience in
renewing or extending similar arrangements. This FSP shall be effective for
financial statements issued for fiscal years beginning after December 15, 2008,
and interim periods within those fiscal years. Early adoption is prohibited.
FSP FAS 157-1, "Application of FASB Statement No. 157 to FASB Statement No.
13 and Other Accounting Pronouncements That Address Fair Value Measurements for
Purposes of Lease Classification or Measurement under Statement 13" -- amends
SFAS No. 157, "Fair Value Measurements", to exclude SFAS No. 13, "Accounting for
Leases", and other accounting pronouncements that address fair value
measurements for purposes of lease classification or measurement under Statement
13. However, this scope exception does not apply to assets acquired and
liabilities assumed in a business combination that are required to be measured
at fair value under SFAS No. 141, "Business Combinations", or No. 141 (revised
2007), "Business Combinations", regardless of whether those assets and
liabilities are related to leases.
FSP FAS 157-2, "Effective Date of FASB Statement No. 157" -- delays the
effective date of SFAS No. 157, "Fair Value Measurements", for nonfinancial
assets and nonfinancial liabilities, except for items that are recognized or
disclosed at fair value in the financial statements on a recurring basis (at
least annually). The delay is intended to allow the Board and constituents
additional time to consider the effect of various implementation issues that
have arisen, or that may arise, from the application of SFAS No. 157. This FSP
defers the effective date of SFAS No. 157 to fiscal years beginning after
November 15, 2008, and interim periods within those fiscal years for items
within the scope of this FSP.
FSP SOP 07-1-1, -- indefinitely delays the effective date of AICPA
Statement of Position 07-1, "Clarification of the Scope of the Audit and
Accounting Guide Investment Companies and Accounting by Parent Companies and
Equity Method Investors for Investments in Investment Companies."
FSP EITF 03-6-1, -- "Determining Whether Instruments Granted in Share-Based
Payment Transactions Are Participating Securities." This FSP provides that
unvested share-based payment awards that contain nonforfeitable rights to
dividends or dividend equivalents (whether paid or unpaid) are participating
Page 24
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
securities and shall be included in the computation of earnings per share
pursuant to the two-class method. The FSP is effective for financial statements
issued for fiscal years beginning after December 15, 2008, and interim periods
within those years. Upon adoption, a company is required to retrospectively
adjust its earnings per share data (including any amounts related to interim
periods, summaries of earnings and selected financial data) to conform with the
provisions in this FSP. Early application of this FSP is prohibited.
EITF Consensuses (EITF):
EITF Issue No. 07-1, "Accounting for Collaborative Arrangements " -- when
entities enter into arrangements to participate in a joint operating activity a
collaborative arrangement may provide that one participant has sole or primary
responsibility for certain activities or that two or more participants have
shared responsibility for certain activities. Participants should evaluate
whether an arrangement is a collaborative arrangement at the inception of the
arrangement based on the facts and circumstances present at that time. Revenue
generated and costs incurred by participants from transactions with parties
should be reported gross or net on the appropriate line item in each
participant's respective financial statements depending on the nature of the
participation. Disclosures should include information about the nature and
purpose of its collaborative arrangements, the entity's rights and obligations
under the collaborative arrangements, the accounting policy for collaborative
arrangements, and the income statement classification and amounts attributable
to transactions arising from the collaborative arrangement. Effective for
financial statements issued for fiscal years beginning after December 15, 2008,
and interim periods within those fiscal years.
EITF Issue No. 07-5, " Determining Whether an Instrument (or Embedded
Feature) Is Indexed to an Entity's Own Stock" -- This Issue addresses the
determination of whether an instrument (or an embedded feature) is indexed to an
entity's own stock, which is the first part of the scope exception in paragraph
11(a) of Statement 133. If an instrument (or an embedded feature) that has the
characteristics of a derivative instrument under paragraphs 6-9 of Statement 133
is indexed to an entity's own stock, it is still necessary to evaluate whether
it is classified in stockholders' equity (or would be classified in
stockholders' equity if it were a freestanding instrument). For example, a
net-cash-settled stock purchase warrant may be indexed to an entity's own stock,
but it is not classified in stockholders' equity. Other applicable authoritative
accounting literature, including Issues 00-19 and 05-2, provides guidance for
determining whether an instrument (or an embedded feature) is classified in
stockholders' equity (or would be classified in stockholders' equity if it were
a freestanding instrument). This Issue does not address that second part of the
scope exception in paragraph 11(a) of Statement 133. Entities are required to
apply the guidance in this issue to fiscal years beginning after December 15,
2008 and interim periods within those fiscal years. Earlier application by an
entity that has previously adopted an alternative accounting policy is not
permitted.
EITF Issue No. 08-3, "Accounting by Lessees for Maintenance Deposits" --
The objective of this Issue is to clarify how a lessee shall account for a
maintenance deposit under an arrangement accounted for as a lease. This Issue
applies to the lessee's accounting for maintenance deposits paid by a lessee
under an arrangement accounted for as a lease that are refunded only if the
lessee performs specified maintenance activities. Maintenance deposits within
the scope of this Issue shall be accounted for as a deposit asset. Lessees shall
continue to evaluate whether it is probable that an amount on deposit will be
returned to reimburse the costs of the maintenance activities incurred by the
lessee. When an amount on deposit is less than probable of being returned, it
shall be recognized as additional expense. When the underlying maintenance is
performed, the maintenance costs shall be expensed or capitalized in accordance
with the lessee's maintenance accounting policy. This Issue is effective for
financial statements issued for fiscal years beginning after December 15, 2008,
including interim periods within those fiscal years. Earlier application by an
entity that has previously adopted an alternative accounting policy is not
permitted.
EITF Issue No. 08-5, "Issuer's Accounting for Liabilities Measured at Fair
Value with a Third-Party Credit Enhancement" -- This issue discusses the
application of fair value to liabilities issued with an inseparable contractual
third-party credit enhancement (e.g., a guarantee). In applying the fair value
option to liabilities, the question arises as to whether the liability and the
Page 25
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
third-party enhancement should be accounted for as: (a) one unit of accounting,
which would result in the third-party guarantee being taken into consideration
in determining the fair value of the liability, or (b) two separate units of
accounting, which would not result in the third-party guarantee being taken into
consideration in determining the fair value of the liability.
The EITF concluded that the scope of this issue applies to a liability that
is issued with an inseparable third-party credit enhancement that is measured or
disclosed at fair value, except a liability with a guarantee provided by the
government or government agencies.
The final consensus requires that an entity: (a) apply the guidance in this
issue prospectively to its first reporting period beginning on or after December
15, 2008; (b) recognize the effect of the change prospectively, with the effect
of initially applying the guidance in this issue included in the change in fair
value in the period of adoption, and (c) include in the period of adoption
disclosure of -- (1) the existence of any third-party credit enhancement on any
issued liability that is within the scope of this issue, (2) the valuation
technique(s) used to measure the fair value of issued liabilities within the
scope of this issue, and (3) any changes from valuation techniques used in prior
periods to measure liabilities within the scope of this issue. Early adoption is
permitted.
EITF Issue No. 08-6, "Equity Method Investment Accounting Considerations"
-- The purpose of this issue is to resolve several accounting issues that arise
in applying the equity method of accounting. Most of these issues arise or
become more prevalent upon the effective date of FASB Statement No. 141 (Revised
2007), "Business Combinations", and (or) FASB Statement No. 160, "Noncontrolling
Interests in Consolidated Financial Statements." This is because the literature
that is being replaced or amended by Statements 141R and 160 have been used by
analogy in addressing certain aspects of applying the equity method of
accounting, which raises the question as to whether these aspects of applying
the equity method of accounting should change upon the effective date of
Statements 141R and 160 (which for calendar year-end companies is January 1,
2009). The specific issues raised with Issue 08-6 include:
Issue 1: How the initial carrying value of an equity method investment
should be determined. In other words, should the initial carrying value of
an equity method investment be determined as if the equity method
investment were any other acquired asset or should it be determined as if
the equity method investment were a business combination? For example,
should transaction costs be capitalized or expensed?
Issue 2: How the difference between the investor's carrying value, as
determined in Issue 1, and the underlying equity of the investee should be
allocated to the underlying assets and liabilities of the investee. In
other words, should the allocation method used be wholly consistent with
the acquisition method included in Statement 141R or should it be only
partially consistent with the acquisition method included in Statement
141R? For example, should the allocation to contingent assets and
liabilities be consistent with the model used in Statement 141R to account
for contingent assets and liabilities or should the allocation to
contingent assets and liabilities be consistent with FASB Statement No. 5,
Accounting for Contingencies , and other generally accepted accounting
principles?
Issue 3: How an impairment assessment of an underlying indefinite-lived
intangible asset of an equity method investment should be performed. In
other words, should the underlying indefinite-lived intangible asset be
tested annually and as part of an other-than-temporary impairment test, or
only as part of an other-than-temporary impairment test?
Issue 4: How should an equity method investee's issuance of shares should
be accounted for?
Issue 5: How should a change in an investment from the equity method to the
cost method be accounted for?
The EITF concluded on these issues:
Page 26
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Issue 1: A cost accumulation model should be used to determine the initial
carrying value of an equity method investment. That is, the initial
carrying value would include transaction costs.
Issue 2: No additional guidance will be provided.
Issue 3: Only an other-than-temporary impairment test should be performed
on the overall investment. There should not be a separate impairment test
for the underlying indefinite-lived intangible assets.
Issue 4: The equity method investee's issuance of shares should be
accounted for as the sale of a proportionate share of the investment, which
would result in a gain or loss in income in many situations.
Issue 5: No gain or loss should be recognized when changing the method of
accounting for an investment from the equity method to the cost method of
accounting.
The guidance in this issue should be applied to transactions that occur in
fiscal years, and interim periods within those fiscal years, beginning on or
after December 15, 2008. Early adoption is not permitted for entities that have
previously adopted an alternative accounting policy.
EITF Issue No. 08-7, "Accounting for Defensive Intangible Assets" -- This
issue discusses the accounting for defensive intangible assets. A defensive
intangible asset, for purposes of this issue, includes all acquired intangible
assets that the acquirer does not intend to actively use, but intend to hold to
prevent its competitors from obtaining access to the asset. The following
questions have arisen in regards to these assets:
Issue 1: Should the acquired defensive intangible asset by accounted for
separately or as part of another related intangible asset (recognized or
unrecognized) of the acquirer?
Issue 2: How should the useful life of the acquired intangible asset be
determined if it is accounted for as a separate asset?
The EITF concluded on these issues:
Issue 1: The value of an acquired defensive intangible asset should be
separately accounted for.
Issue 2: The date at which the defensive asset is expected to be
"effectively abandoned" should be used to determine the length of its
useful life. In effect, the amortization period would be the period of time
over which the defensive intangible asset is expected to provide defensive
value to the entity. This accounting includes in-process R&D defensive
intangible assets.
The guidance in this issue should be applied prospectively to intangible
assets acquired on or after the beginning of the first annual reporting period
beginning on or after December 15, 2008.
EITF Issue No. 08-8, "Accounting for an Instrument (or an Embedded Feature)
with a Settlement Amount That Is Based on the Stock of an Entity's Consolidated
Subsidiary " -- Paragraph 11(a) of FASB Statement No. 133, "Accounting for
Derivative Instruments and Hedging Activities," provides for a contract issued
or held by a reporting entity that satisfies the following two conditions to not
be considered a derivative financial instrument for purposes of that statement:
(a) the contract is indexed to the entity's own stock and (b) the contract is
classified in stockholders' equity. When the instrument (or embedded feature)
under consideration is one whose "payoff to the counterparty is based, in whole
or in part, on the stock of a consolidated subsidiary," the question arises as
to whether such an instrument (or embedded feature) should be considered indexed
to the entity's own stock. Certain aspects of this question have been dealt with
in the past by the EITF. For example, EITF Issue No. 00-6, "Accounting for
Freestanding Derivative Financial Instruments Indexed to, and Potentially
Settled in, the Stock of a Consolidated Subsidiary," indicates that freestanding
instruments issued by the parent whose payoff is based in whole or in part on
the stock of a consolidated subsidiary is not indexed to the parent's own stock
(i.e., it would not satisfy the first of the two conditions in paragraph 11(a)
of Statement 133). In addition, EITF Issue No. 99-1, "Accounting for Debt
Convertible into the Stock of a Consolidated Subsidiary," indicates that debt
issued by a parent or subsidiary that is convertible into the subsidiary's own
stock can qualify for the scope exception in paragraph 11(a). Many believe that
Page 27
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
the conclusions in Issues 99-1 and 00-6 are inherently inconsistent. This
inherent inconsistency is expected to become magnified upon the effective date
of FASB Statement No. 160, "Noncontrolling Interests in Consolidated Financial
Statements." This is due to Statement 160 requiring the classification of the
noncontrolling interest in a subsidiary within equity in the consolidated
financial statements. Prior to the effective date of Statement 160, the
noncontrolling (or minority) interest is most often reflected in the mezzanine
of the balance sheet between liabilities and equity. Upon the change in the
classification of the noncontrolling interest, it is expected that more
instruments will qualify for the second of the two conditions included in
paragraph 11(a) of Statement 133 (i.e., the contract is classified in
stockholders' equity). This will, in turn, place additional attention or
prominence on the evaluation of whether the instrument (or embedded feature)
should be considered indexed to the entity's own stock (i.e., whether the
instrument qualifies for the first of the two conditions included in paragraph
11(a) of Statement 133). As such, this issue was added to the EITF's agenda to
address:
Issue 1: Whether instruments within the scope of Issue 08-8 should or
should not be precluded from being considered indexed to the entity's own
stock for purposes of the consolidated financial statements
Issue 2: Whether the instrument should be classified as: (a) a component of
the noncontrolling interest reflected in the stockholders' equity section
of the consolidated balance sheet, or (b) a component of the controlling
interest reflected in the stockholders' equity section of the consolidated
balance sheet.
The EITF concluded on these issues:
Issue 1: An instrument within the scope of this issue is not precluded from
being considered indexed to the entity's own stock for purposes of the
consolidated financial statements of the parent. For purposes of
determining whether the instrument is, in fact, indexed to the entity's own
stock, the guidance in EITF Issue No. 07-5, "Determining Whether an
Instrument (or an Embedded Feature) Is Indexed to an Entity's Own Stock,"
should be considered. Issue 07-5 and other applicable literature (e.g.,
EITF Issue No. 00-19, "Accounting for Derivative Financial Instruments
Indexed to, and Potentially Settled in, a Company's Own Stock ") should be
referred to for purposes of determining the classification of the
instrument.
Issue 2: The presentation within stockholders' equity of an
equity-classified instrument within the scope of this issue is not
dependent on whether the instrument was issued by the parent or subsidiary.
In other words, such an instrument should be presented as a component of
the noncontrolling interest reflected in the stockholders' equity section
of the consolidated balance sheet if the instrument was issued by either
the parent or the subsidiary. If, however, the instrument was issued by the
parent and it goes unexercised, the carrying amount of the instrument would
be reclassified from the noncontrolling interest to the controlling
interest at that time. Note: The guidance in this issue is not applicable
to instruments within the scope of and accounted for in accordance with
FASB Statement No. 123 (Revised 2004), "Share-Based Payment," and EITF
Issue No. 96-18, "Accounting for Equity Instruments That Are Issued to
Other Than Employees for Acquiring, or in Conjunction with Selling, Goods,
or Services." However, once an instrument ceases to be accounted for in
accordance with Statement 123R or Issue 96-18, the guidance in this issue
is applicable to that instrument.
The consensus requires that an entity: (a) apply the guidance in this issue
for fiscal years, and interim periods within those fiscal years, beginning after
December 15, 2008; (b) apply the guidance to outstanding instruments as of the
beginning of the fiscal year in which this issue is adopted; (c) use the fair
value of an outstanding contract that was previously classified as a derivative
Page 28
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
asset or liability as its net carrying amount at the date of adoption; (d)
reclassify the net carrying amount of the outstanding contracts to
noncontrolling interest at the date of adoption; and (e) provide any transition
disclosure required by paragraphs 17 and 18 of FASB Statement No. 154,
"Accounting Changes and Error Corrections." Early adoption is not permitted.
Results of Operations
Three Months Ended August 31, 2008 and 2007
Net revenue from sales, leases and service of our EECP(R) systems for the
three months ended August 31, 2008 and 2007, was $1,311,721 and $1,340,076,
respectively, which represented a decrease of $28,355, or 2%. We reported a net
loss attributable to common stockholders of $549,971 and $18,786 for the first
quarter of fiscal 2009 and 2008, respectively. The increase in the net loss was
primarily due to increases in our operating expenses from the comparative prior
period. Our net loss per diluted common share was $0.01 for the three-month
period ended August 31, 2008 compared to a net loss of $0.00 per diluted common
share for the three-month period ended August 31, 2007.
Revenues
Revenue from equipment sales increased approximately 33% to $656,469 for
the three-month period ended August 31, 2008 as compared to $493,268 for the
same period in the prior year. The increase in equipment sales is due primarily
to a 40% increase in the number of equipment shipments offset slightly by a
decrease in the average blended per unit sale price. The 40% increase in the
number of units sold reflects a 50% increase in new unit sales, both
domestically and internationally, decreased minimally by the number of used unit
models sold from the prior fiscal quarter.
We believe the decline in the sales price per unit reflects weakened demand
in the refractory angina market as existing capacity is more fully utilized,
coupled with increased direct and indirect competition. We anticipate that
demand for EECP(R) systems will remain soft unless there is greater clinical
acceptance for the use of EECP(R) therapy in treating patients with angina or
angina equivalent symptoms who meet the current reimbursement guidelines or an
expansion of the current CMS national reimbursement policy to include some or
all Class II & III heart failure patients. Patients with angina or angina
equivalent symptoms eligible for reimbursement under current policies include
many with serious comorbidities, such as heart failure, diabetes, peripheral
vascular disease and/or others. Despite this, many cardiology clinicians appear
to be waiting for approval of reimbursement coverage for heart failure as a
primary indication before they will move forward with the treatment of ischemic
heart failure patients with angina equivalent symptoms. Reluctance to bill for
ischemic heart failure patients under the current coverage guidelines, and
failure to get or maintain adequate reimbursement coverage for angina and heart
failure would adversely affect our business prospects. We anticipate that a
prevailing trend of declining prices will continue in the immediate future as
our competition attempts to capture greater market share through pricing
discounts. The average price of new systems sales declined by 22% which was
mainly due to increased competition, in the first quarter of fiscal 2009
compared to the same three-month period in the prior year and the average sales
price of used systems declined 11% in the first quarter of fiscal 2009. We
continue to reorganize certain territory responsibilities in our sales
department due to vacant and/or unproductive territories.
Our revenue from the sale of EECP(R) systems and related products to
international distributors in the first quarter of fiscal 2009 increased
approximately 103% to $315,984 compared to $155,991 in the same three-month
period in the prior year reflecting increased sales volume.
Our revenue from equipment rental and services decreased 23% to $655,225 in
the first quarter of fiscal 2009 from $846,808 in the first quarter of fiscal
year 2008. Revenue from equipment rental and services represented 50% of total
revenue in the first quarter of fiscal 2009 and 63% in the same quarter of
fiscal 2008. The decrease in revenue generated from equipment rentals and
services is due to a decrease in the service business, with respect to service
contract sales, and service related income generated from units not under
contract, as well as, a decrease in accessories and service parts shipped
compared to the same quarter of the prior fiscal year.
Page 29
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Gross Profit
Gross profit declined to $500,562, or 38% of revenues, for the first
quarter of fiscal 2009 compared to $684,739, or 51% of revenues, for the same
quarter of fiscal 2008. The decrease in the gross profit margin as a percentage
of revenue for the first quarter of fiscal 2009 compared to the same quarter of
the prior fiscal year was mainly due to lower revenue generated from equipment
rentals and services due to a decrease in the service business, with respect to
service contract sales, and service related income generated from units not
under contract, as well as, a decrease in accessories and service parts shipped
of $169,000, or 24%. The decline in gross profit related to equipment sales,
when compared to the same three-month period in the prior year in absolute
dollars is principally due to the lower sales price per unit from the first
quarter of fiscal 2008.
In addition, gross profits are dependent on a number of factors,
particularly the mix of EECP(R) models sold domestically and internationally and
their respective average selling prices, the mix of EECP(R) units sold, rented
or placed during the period, the ongoing costs of servicing such units, and
certain fixed period costs, including facilities, payroll and insurance. Gross
profit margins are generally less on non-domestic business due to the use of
distributors resulting in lower selling prices. Consequently, the gross profit
realized during the current period may not be indicative of future margins.
Selling, General and Administrative
Selling, general and administrative ("SG&A") expenses for the first quarter
of fiscal 2009 and 2008 were $943,759, or 72% of revenues, and $558,156, or 42%
of revenues, respectively, reflecting a increase of $385,603 or approximately
69%. The increase in SG&A expenditures in the first quarter of fiscal 2009
resulted primarily from increased direct expenditures of $66,078 due to
increased sales personnel and associated costs including travel, offset by
decreases in other sales related costs. Marketing expenses increased $56,202 due
to increased expenditures in personnel and their associated costs in the
marketing and clinical application support areas, plus higher market research,
product promotion, advertising, and trade show expenses. Administrative expenses
increased $263,323 as a result of increased expenditures in professional fees
related to accounting, legal and consulting services, corporate expenses, and
directors' compensation offset slightly by decreases in insurance expenses and
other miscellaneous administrative expenses.
During the first quarter of fiscal 2009, there was no change in the
Company's provision for doubtful accounts compared to the first quarter of
fiscal 2008 when the Company reversed a provision for doubtful accounts of
$25,246.
Research and Development
Research and development ("R&D") expenses of $132,347, or 10% of revenues,
for the first quarter of fiscal 2009 decreased by $6,828, or 10%, from $139,175,
or 10% of revenues, for the first quarter of fiscal 2008. The decrease is
primarily attributable to a decrease in product development spending, offset by
an increase in regulatory affairs expenses related to obtaining regulatory
clearance for the ambulatory ECG recorders and Holter ABPM combination recorders
and ultrasound scanners.
Interest Expense and Financing Costs
The Company had no interest expense and financing costs for the first
quarter of fiscal 2009 compared to $16,666 for the same quarter in the prior
year. Interest expense primarily reflects interest on loans secured to refinance
the November 2000 purchase of the Company's headquarters and warehouse facility.
The decrease is a direct result of the sale-leaseback agreements for the
Company's headquarters and warehouse facility, which occurred during the first
quarter of fiscal 2008.
Page 30
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Interest and Other Income, Net
Interest and other income for the first quarter of 2009 and 2008, were
$16,012 and $12,331, respectively. Interest income reflects interest earned on
the Company's cash balances.
Recognition of Deferred Gain on Sale of Building
The Recognition of Deferred Gain on Sale of Building for the first quarter
of 2009 and 2008, were $13,311 and $4,437, respectively. The gain resulted from
the Company's sale-leaseback of its facility. See Note G.
Income Tax Expense, Net
During the first quarters of fiscal 2009 and 2008 we recorded a provision
for income taxes of $3,750 and $6,296, respectively.
As of August 31, 2008, the recorded deferred tax assets were $20,001,852,
reflecting an increase of $182,500 during the first quarter of fiscal 2009,
which was offset by a valuation allowance of the same amount.
Ultimate realization of any or all of the deferred tax assets is not
assured due to significant uncertainties and material assumptions associated
with estimates of future taxable income during the carryforward period. In
November 2005, we concluded that, based upon the weight of available evidence,
it was "more likely than not" that the net deferred tax asset would not be
realized and increased the valuation allowance to bring the net deferred tax
asset carrying value to zero.
Liquidity and Capital Resources
Cash and Cash Flow
We have financed our operations primarily from working capital, a private
equity financing, and by the sale of our facility under a leaseback agreement.
At August 31, 2008, we had cash and cash equivalents of $2,140,403 and working
capital of $2,436,625 compared to cash and cash equivalents of $2,653,999 and
working capital of $2,851,901 at May 31, 2008.
Cash used in operating activities was $512,217 during the first quarter of
fiscal 2009, which consisted of a net cash loss after adjustments of $503,027
and cash used by operating assets and liabilities of $9,190. The changes in the
accounts balances primarily reflects increases in inventory of $193,041,
accounts receivable of $163,836, and other current assets of $76,377, which were
primarily offset by an increase in accounts payable, accrued expenses, and other
current liabilities of $318,546. Net accounts receivable were 67% of revenues
for the three-month period ended August 31, 2008, as compared to 54% for the
three-month period ended August 31, 2007, and accounts receivable turnover
decreased to 6.5 times as of August 31, 2008, as compared to 7.8 times as of
August 31, 2007.
Standard payment terms on our domestic equipment sales are generally net 30
to 90 days from shipment and do not contain "right of return" provisions. We
have historically offered a variety of extended payment terms, including
sales-type leases, in certain situations and to certain customers in order to
expand the market for our EECP(R) therapy system products in the US and
internationally. Such extended payment terms were offered in lieu of price
concessions, in competitive situations, when opening new markets or geographies
and for repeat customers. Extended payment terms cover a variety of negotiated
terms, including payment in full - net 120, net 180 days or some fixed or
variable monthly payment amount for a six to twelve month period followed by a
balloon payment, if applicable. During the three-month periods ended August 31,
2008 and August 31, 2007, there were no revenues generated from sales in which
initial payment terms were greater than 90 days and we offered no sales-type
leases during either period. In general, reserves are calculated on a formula
Psge 31
Vasomedical, Inc. and Subsidiaries
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
basis considering factors such as the aging of the receivables, time past due,
and the customer's credit history and their current financial status. In most
instances where reserves are required, or accounts are ultimately written-off,
customers have been unable to successfully implement their EECP(R) therapy
program. As we are creating a new market for the EECP(R) therapy and recognizing
the challenges that some customers may encounter, we have opted, at times, on a
customer-by-customer basis, to recover our equipment instead of pursuing other
legal remedies, which has resulted in our recording of a reserve or a write-off.
Investing activities used net cash of $1,379 for the purchase of fixed
assets during the three-month period ended August 31, 2008.
The Company had no financing activities during the three-month period ended
August 31, 2008.
The following table presents the Company's expected cash requirements for
contractual obligations outstanding as of August 31, 2008.
Due thru Due thru Due thru
9/1/2008 and 9/1/2009 and 9/1/2011 and Due
Total 8/31/2009 8/31/2011 8/31/2013 Thereafter
------------------------------------------------------------------
Operating Leases $ 612,182 $ 144,163 $ 305,856 $ 162,163 $ -
Other long-term liabilities 320,000 240,000 80,000 - -
------------------------------------------------------------------
Total Contractual Cash
Obligations $ 932,182 $ 384,163 $ 385,856 $ 162,163 $ -
==================================================================
Liquidity
During the first quarter of fiscal 2008, events took place, that allowed us
to raise additional capital through a private equity financing and by the sale
of our facility under a leaseback agreement. See Note A for details of these
events.
Based on our current operations and the amounts received from the
transactions described in Note A, we believe that we have sufficient working
capital to continue our operations through at least the next twelve months.
Effects of Inflation
We believe that inflation and changing prices over the past year have had a
significant impact on our revenue or on our results of operations.
Page 32
Vasomedical, Inc. and Subsidiaries
ITEM 3 - CONTROLS AND PROCEDURES
We carried out an evaluation, under the supervision and with the
participation of our management, including our Chief Executive Officer and Chief
Financial Officer, of the effectiveness of the design and operation of our
disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based
upon that evaluation, the Chief Executive Officer and Chief Financial Officer
concluded that, as of August 31, 2008, our disclosure controls and procedures
are effective to provide reasonable assurances that such disclosure controls and
procedures satisfy their objectives and that the information required to be
disclosed by us in the reports we file under the Exchange Act is recorded,
processed, summarized and reported within the required time periods. There were
no changes during the fiscal quarter ended August 31, 2008 in our internal
controls or in other factors that could have materially affected, or are
reasonably likely to materially affect, our internal control over financial
reporting.
Page 33
Vasomedical, Inc. and Subsidiaries
PART II - OTHER INFORMATION
ITEM 1 - LEGAL PROCEEDINGS:
None.
ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS:
None
ITEM 3 - DEFAULTS UPON SENIOR SECURITIES:
None
ITEM 4 - SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None
ITEM 5 - OTHER INFORMATION:
None
ITEM 6 - EXHIBITS
Exhibits
31 Certifications pursuant to Rules 13a-14(a) as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
32 Certifications pursuant to 18 U.S.C. Section 1350 as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002.
Page 34
In accordance with the requirements of the Exchange Act, the Registrant
caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
VASOMEDICAL, INC.
By: /s/ John C.K Hui
-----------------------------------------
John C.K. Hui
President and Chief Executive Officer
(Principal Executive Officer)
/s/ Tricia Efstathiou
-----------------------------------------
Tricia Efstathiou
Chief Financial Officer
(Principal Financial and Accounting
Officer)
Date: October 15, 2008
Page 35